Your browser doesn't support javascript.
loading
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Park, Seong Joon; Kim, Seung-Mi; Moon, Jai-Hee; Kim, Jeong Hee; Shin, Jae-Sik; Hong, Seung-Woo; Shin, Yu Jin; Lee, Dae-Hee; Lee, Eun Young; Hwang, Ih-Yeon; Kim, Jeong Eun; Kim, Kyu-Pyo; Hong, Yong Sang; Lee, Won-Keun; Choi, Eun Kyung; Lee, Jung Shin; Jin, Dong-Hoon; Kim, Tae Won.
Afiliação
  • Park SJ; Innovative Cancer Research, ASAN Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Kim SM; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Moon JH; Innovative Cancer Research, ASAN Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Kim JH; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Shin JS; Department of Biosciences and Bioinformatics, Myongji University, 116 Myongji-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, 449-728, Republic of Korea.
  • Hong SW; Innovative Cancer Research, ASAN Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Shin YJ; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Lee DH; Innovative Cancer Research, ASAN Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Lee EY; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Hwang IY; Innovative Cancer Research, ASAN Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Kim JE; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Kim KP; Innovative Cancer Research, ASAN Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Hong YS; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Lee WK; Innovative Cancer Research, ASAN Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Choi EK; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Lee JS; Innovative Cancer Research, ASAN Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
  • Jin DH; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Kim TW; Innovative Cancer Research, ASAN Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.
Tumour Biol ; 37(4): 4323-30, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26493999
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Caderinas / Inibidores de Histona Desacetilases / Receptores ErbB / Cloridrato de Erlotinib / Ácidos Hidroxâmicos Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Caderinas / Inibidores de Histona Desacetilases / Receptores ErbB / Cloridrato de Erlotinib / Ácidos Hidroxâmicos Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article